American Society of Hirudotherapy

Identification and cloning of an invertebrate-type lysozyme from Eisenia andrei

Basic science published in Dev Comp Immunol (2009)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Antimicrobial ResistanceGenomics & ProteomicsJosková R et al. · Developmental and comparative immunology, 2009

Abstract

Lysozyme is a widely distributed antimicrobial protein having specificity for cleaving the beta-(1,4)-glycosidic bond between N-acetylmuramic acid (NAM) and N-acetylglucosamine (GlcNAc) of peptidoglycan of the bacterial cell walls and thus efficiently contributes to protection against infections caused mainly by Gram-positive bacteria. In the present study, we assembled a full-length cDNA of a novel invertebrate-type lysozyme from Eisenia andrei earthworm (EALys) by RT-PCR and RACE system. The primary structure of EALys shares high homology with other invertebrate lysozymes; however the highest, 72% identity, was shown for the destabilase I isolated from medicinal leech. Recombinant EALys expressed in Escherichia coli exhibited the lysozyme and isopeptidase activity. Moreover, real-time PCR revealed increased levels of lysozyme mRNA in coelomocytes of E. andrei after the challenge with both Gram-positive and Gram-negative bacteria.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsBacillus subtilisBacterial AdhesionCarbon-Nitrogen LyasesChitinasesCloning, MolecularEchinodermataEndopeptidasesEscherichia coliEscherichia coli InfectionsGlucosamineGram-Positive Bacterial InfectionsHirudo medicinalisHost-Pathogen InteractionsHydrolysisMuramic AcidsMuramidaseOligochaetaSequence HomologyVirulence

Summary

Researchers cloned a full-length cDNA encoding a novel invertebrate-type lysozyme, EALys, from the earthworm Eisenia andrei; it shares 72% identity with medicinal leech destabilase I, and recombinant EALys expressed in E. coli showed lysozyme and isopeptidase activity, with increased lysozyme mRNA after bacterial challenge.

Context

This study identified and cloned a novel invertebrate-type lysozyme (EALys) from the earthworm Eisenia andrei, noting that its primary structure shares the highest identity (72%) with destabilase I from the medicinal leech. Recombinant EALys exhibited both lysozyme and isopeptidase activity, and mRNA levels increased in coelomocytes after bacterial challenge with Gram-positive and Gram-negative species. The study concerns an earthworm enzyme and provides comparative molecular context for the invertebrate-type lysozyme family that includes leech destabilase. No leech material, secretions, or therapeutic applications are examined.

Citation

Reference (Vancouver style)

Josková R, Silerová M, Procházková P, Bilej M. Identification and cloning of an invertebrate-type lysozyme from Eisenia andrei. Dev Comp Immunol. 2009;33(8):932-938. doi:10.1016/j.dci.2009.03.002. PMID: 19454335

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.